Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
68°
Mostly Cloudy
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Best of 2023
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exscientia Ltd ADR
(NQ:
EXAI
)
5.030
+0.270 (+5.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Exscientia Ltd ADR
< Previous
1
2
3
4
5
6
Next >
Exscientia is the Sniper of the AI Drug Discovery Industry
July 27, 2023
News of a $50 million investment by artificial intelligence (AI) leader Nvidia Co. (Nasdaq: NVDA) into AI-powered drug discovery company Recursion
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Exscientia Initiates Prospective Observational Study in Ovarian Cancer
July 18, 2023
From
Exscientia
Via
Business Wire
First Patient Enrolled in Phase 1/2 “ELUCIDATE” Trial Assessing GTAEXS617 in Advanced Solid Tumours
July 10, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces Expansion of its Technology Leadership Team
June 29, 2023
From
Exscientia
Via
Business Wire
Exscientia to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 06, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Business Update for First Quarter 2023
May 24, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Highlights "The Future of AI-enabled Drug Discovery" at SLAS Europe
May 22, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Report First Quarter 2023 Financial Results on May 24, 2023
May 17, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces Sixth Molecule Created Through Generative AI Platform to Enter Clinical Stage
May 15, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Appoints Harvard Professor Franziska Michor, Ph.D. to Board of Directors
May 03, 2023
From
Exscientia plc
Via
Business Wire
Data Presented at AACR 2023 Highlights Exscientia’s Clinical and Preclinical Development
April 19, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Business and Financial Update for the Full Year 2022
March 23, 2023
From
Exscientia
Via
Business Wire
Exscientia to Report Full Year 2022 Financial Results on March 23, 2023
March 16, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Present Data Highlighting Pipeline and Precision Medicine Platform at AACR
March 15, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces Expansion of its Precision Oncology Pipeline
March 14, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces Collaboration with Charité to Advance Development of Precision Medicine Platform
March 07, 2023
From
Exscientia plc
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in March
February 22, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
February 02, 2023
From
Exscientia plc
Via
Business Wire
Exscientia Presents Novel Immuno-Oncology Biomarker for EXS-21546 at the ESMO I-O Annual Congress
December 06, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
November 28, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Business and Financial Update for the Third Quarter 2022
November 15, 2022
From
Exscientia plc
Via
Business Wire
Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments
November 14, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Report Third Quarter 2022 Financial Results on November 15, 2022
November 08, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Expands Biologics Design Capability with Automated Laboratory
November 03, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in November
November 01, 2022
From
Exscientia
Via
Business Wire
Exscientia Wins Prix Galien USA 2022 Digital Health Solution Award
October 28, 2022
From
Exscientia plc
Via
Business Wire
Exscientia Presents Novel Patient Stratification and Biomarker Data for GTAEXS-617 at the 34th EORTC-NCI-AACR Annual Symposium
October 26, 2022
From
Exscientia plc
Via
Business Wire
Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes
September 20, 2022
From
Exscientia
Via
Business Wire
Exscientia Welcomes Caroline Rowland as Chief People Officer
September 08, 2022
From
Exscientia plc
Via
Business Wire
Exscientia to Present at Upcoming Investor Conferences in September
September 07, 2022
From
Exscientia
Via
Business Wire
< Previous
1
2
3
4
5
6
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.